Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

New antibiotics “not enough” to solve resistance
pills
More than 25,000 people die every year from antibiotic resistant infections.
A broader one health approach is needed as well as new drugs, says charity

Developing new antibiotics will not be enough to tackle resistance long-term, a charity has warned following news that a government review will aim to address the lack of new drugs.

Prime Minister David Cameron last week announced that he had commissioned an independent review to determine why no new antibiotics have come onto the market for 25 years.

Mark Dosher, secretary of the Bella Moss Foundation (BMF), said that while new drugs form a part of the solution, resistance “can't be solved by pharmacology alone.”

The introduction of new drugs is a “double-edged sword,” he continues, as the creation of new drugs encourages usage, which in turn leads to resistance.

Around 25,000 people in Europe die every year due to antibiotic resistant infections.

Politicians, human healthcare and veterinary professionals need to think about the long-term picture, according to BMF.

“Without also developing and implementing strategies to reduce antimicrobial use, to use these drugs more wisely, and to develop non-antibiotic ways to manage bacterial infections, we could find ourselves in exactly the same position [in the future],” says Tim Nuttal, Edinburgh Veterinary School academic and BMF advisor.

A one health approach is needed, Mr Dosher adds, taking into account hygiene and the environment in which bugs live.

He explains: “For example, there are things we can do now with the environments in hospitals that could have an effect today – such as paint that kills bacteria when activated by light, or ventilation additives. 


“It has to be recognised that new antibiotics could result in new resistant pathogens so we have to look into other areas, from hygiene and environment to the lifestyle of individuals and which people – and animals – are more prone to infection.

“We need to be looking 50-100 years into the future – anything other than that will just repeat mistakes with AMR that have already been made.” 


The government review will be led by internationally respected ecologist Jim O'Neill. Along with a team of experts he aims to stimulate investment in new antibiotics.

Become a member or log in to add this story to your CPD history

Greyhound Board announces change to vaccination guidance

News Story 1
 The Greyhound Board of Great Britain has published new vaccination guidance, with all greyhounds registered from 1 January, 2027 required to have the L4 leptospirosis vaccination, rather than L2.

The change comes in response to the reduced availability of the 'L2' Leptospirosis vaccine across the UK, and aims to support best biosecurity practice across the racing greyhound population.

GBGB veterinary director Simon Gower, said "While rare, Leptospirosis is a serious infectious disease that can affect both dogs and humans, so it is vital that we offer our greyhounds the broadest possible protection.  

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.